Evaxion A/S
Evaxion A/S is a biotechnology company focused on healthcare diagnostics, developing and commercializing AI-driven vaccine and drug discovery platforms.
Business. Evaxion A/S (EVAX.O) is a biotechnology and medical research company operating within the healthcare diagnostics sector. The firm is headquartered in Denmark and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
4 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Evaxion A/S (EVAX.O) is a biotechnology and medical research company operating within the healthcare diagnostics sector. The firm is headquartered in Denmark and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Evaxion maintains a capital structure with no debt, as indicated by a debt-to-equity ratio of 0.0, and a total equity of $2.6 million. The company's liquidity position is unclear due to the absence of balance-sheet inputs and no going-concern language in source documents. The market capitalization of $34.4 million suggests a small-cap profile, with a price-to-earnings ratio of 28.78, indicating a premium valuation relative to earnings.
The company's profitability is mixed, with a net income of $1.2 million but an operating loss of $4.4 million. The return on equity of 45.85% is strong, but this is likely driven by the low equity base rather than operational efficiency. The company's performance is not benchmarked against industry medians due to the lack of industry-specific metrics in the provided data.
Evaxion's revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no geographic breakdown provided. The absence of segment or geographic data limits the ability to assess diversification risks or growth opportunities in different markets.
The company's growth trajectory is uncertain, with no specific revenue growth rates or outlooks provided in the data. Analysts have assigned a mean price target of $11.25, with a median of $10.00, suggesting a potential upside from the current market price of $4.12. However, the lack of detailed revenue history and forward-looking guidance makes it difficult to assess the sustainability of this growth.
Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language. The dilution risk is currently low, but the company may face pressure to raise additional capital if it continues to operate at a loss. No specific dilution sources are identified in the data, and the probability of near-term dilution remains low.
Recent events and filings are not detailed in the provided data, so no specific recent developments can be reported. The company's financial statements and analyst estimates are the primary sources of information, with no additional transcripts or filings referenced.
- Evaxion is a biotechnology company with a focus on healthcare diagnostics and AI-driven drug discovery.
- The company has a strong return on equity but operates at a significant operating loss.
- The company's capital structure is entirely equity-based, with no debt.
- Analysts have assigned a mean price target of $11.25, indicating potential upside from the current market price.
- The company's liquidity risk cannot be assessed due to missing balance-sheet data.
- The company's growth trajectory is uncertain, with no detailed revenue history or forward-looking guidance provided.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue $0.00, −100,0% YoY; Operating income +63,1% YoY.
- ▍Revenue $0.00, −100,0% YoY
- ▍Operating income +63,1% YoY
- ▍Net income −63,0% YoY
Revenue $7.5M, +148,3% YoY; Operating income +274,6% YoY.
- ▍Revenue $7.5M, +148,3% YoY
- ▍Operating income +274,6% YoY
- ▍Net income +338,6% YoY
- ▍Net margin 61.6%
Revenue $37.0k, −76,0% YoY; Operating income +5,3% YoY.
- ▍Revenue $37.0k, −76,0% YoY
- ▍Operating income +5,3% YoY
- ▍Net income +22,1% YoY
- ▍Net margin -13056.8%
Revenue $0.00, −100,0% YoY; Operating income +12,0% YoY.
- ▍Revenue $0.00, −100,0% YoY
- ▍Operating income +12,0% YoY
- ▍Net income −232,3% YoY
Revenue $122.0k; Operating income -$4.0M.
- ▍Revenue $122.0k
- ▍Operating income -$4.0M
- ▍Net margin -2974.6%
Revenue $3.0M; Operating income -$1.7M.
- ▍Revenue $3.0M
- ▍Operating income -$1.7M
- ▍Net margin -64.1%
Revenue $154.0k; Operating income -$4.6M.
- ▍Revenue $154.0k
- ▍Operating income -$4.6M
- ▍Net margin -4024.7%
Revenue $51.0k; Operating income -$4.4M.
- ▍Revenue $51.0k
- ▍Operating income -$4.4M
- ▍Net margin 2341.2%
Revenue $7.5M, +125,1% YoY; Operating income +54,8% YoY.
- ▍Revenue $7.5M, +125,1% YoY
- ▍Operating income +54,8% YoY
- ▍Net income +27,1% YoY
- ▍Free cash flow +28,7% YoY
- ▍Net margin -102.4%
Revenue $3.3M, +4 480,8% YoY; Operating income +33,6% YoY.
- ▍Revenue $3.3M, +4 480,8% YoY
- ▍Operating income +33,6% YoY
- ▍Net income +52,2% YoY
- ▍Free cash flow +53,9% YoY
- ▍Net margin -316.0%
Revenue $73.0k; Operating income +12,1% YoY.
- ▍Revenue $73.0k
- ▍Operating income +12,1% YoY
- ▍Net income +4,5% YoY
- ▍Free cash flow +5,3% YoY
- ▍Net margin -30308.2%
Operating income +2,2% YoY; Net income +5,6% YoY.
- ▍Operating income +2,2% YoY
- ▍Net income +5,6% YoY
- ▍Free cash flow +10,7% YoY
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,17 |
| Revenue | —no estimate | —no estimate | 5,3M USD |
| Operating income | —no estimate | —no estimate | -13,2M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Evaxion A/S Market data — financials · 2026-05-27
- Evaxion A/S Market data — analyst estimates · 2026-05-27